AcuteCVDays - Week 1 : Optimal medical treatment following acute coronary syndrome anno 2024

Antithrombotic treatment is an important component of the management of all patients presenting with ACS. The specific choice and combination of therapy, the time of its initiation, and the treatment duration depend on various patient and procedural factors. Which of the following is not included among the antithrombotic therapy recommendations of 2023 ESC ACS Guideline?
 
If patients presenting with ACS stop DAPT to undergo coronary artery bypass grafting, it is recommended they resume DAPT after surgery for at least 12 months.
In patients who are event-free after 3–6 months of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a P2Y12 receptor inhibitor) should be considered.
Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy.
De-escalation of antiplatelet therapy in the first 30 days after an ACS event is not recommended.
{"name":"AcuteCVDays - Week 1 : Optimal medical treatment following acute coronary syndrome anno 2024", "url":"https://www.quiz-maker.com/QV0FHLU62","txt":"Antithrombotic treatment is an important component of the management of all patients presenting with ACS. The specific choice and combination of therapy, the time of its initiation, and the treatment duration depend on various patient and procedural factors. Which of the following is not included among the antithrombotic therapy recommendations of 2023 ESC ACS Guideline?   .quiz-container.quiz-embed {padding: 0!important;} BODY .qp_container{padding: 0!important; margin-top:0!important; margin-bottom: 0!important} .qp_b{max-width:100%;} BODY .qp_bo{max-width:100%;} .qp_t{padding-left:0;} qp_i{margin-right: 10px; margin-bottom: 25px;} .qp_a INPUT[type='radio']{margin-right: 10px; margin-bottom: 25px;} @media only screen and (max-width: 480px){.qp_flex.cf2 .qp_flexc{width: 100%;!important;}}","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by: Quiz Maker